Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement

Nephrology Dialysis Transplantation

Volumn 28, Issue 6, 2013, Pages 1346-1359

  Locatelli, Francesco ^a   Bárány, Peter ^b   Covic, Adrian ^c   De Francisco, Angel ^d   Del Vecchio, Lucia ^a   Goldsmith, David ^e   Hörl, Walter ^f   London, Gerard ^g,h   Vanholder, Raymond ⁱ   Van Biesen, Wim ⁱ  

^a A MANZONI HOSPITAL   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^h Hospital Manhes   (France)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anaemia; Chronic kidney disease; Erythropoiesis stimulating agents; Iron; Mortality

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FERRITIN BLOOD LEVEL; FOOD AND DRUG ADMINISTRATION; GOOD CLINICAL PRACTICE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT INDICATION;

ANAEMIA; CHRONIC KIDNEY DISEASE; ERYTHROPOIESIS STIMULATING AGENTS; IRON; MORTALITY;

ANEMIA; DISEASE MANAGEMENT; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84879836673     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft033     Document Type: Review

References (66)

1. Zoccali C, Abramowicz D, Cannata-Andia JB et al. European Best Practice Guidelines; European Renal Best Practice. European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrol Dial Transplant 2008; 23: 2162-2166
2. Locatelli F, Covic A, Eckardt KU et al. ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-354
3. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2007 Update of Hemoglobin Target. Am J Kidney Dis 2007; 49(suppl 2): 51-5179
4. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 26(suppl 3): 1-145
5. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
6. Locatelli F, Aljama P, Canaud B et al. Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010; 25: 2846-2850
7. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279-335
8. Hollowell JG, van Assendelft OW, Gunter EW et al. Hematological and iron-related analytes-reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 2005; 11: 1-156
9. Centers for disease control and prevention: recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep 1998; 47: 1-29
10. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): ii1-ii47
11. World Health Organization. Iron Deficiency Anaemia: Assessment, Prevention and Control. A Guide for Programme Managers. Geneva, Switzerland:World Health Organization, 2001
12. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107: 1747-1750
13. Hoobler IM, Hunscher HA. Hemoglobin differences between blacks and whites. Am J Clin Nutr 1977; 30: 1935-1937
14. Beutler E, Felitti VJ, Koziol JA et al. Penetrance of 845G?A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218
15. Stancu S, Barsan L, Stanciu A et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010; 5: 409-416
16. Stancu S, Stanciu A, Zugravu A et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 2010; 55: 639-647
17. Lawler EV, Bradbury BD, Fonda JR et al. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol 2010; 5: 667-672
18. Locatelli F, Del Vecchio L. Erythropoietic response to erythropoiesis- stimulating agents and outcome: should we give up the haemoglobin target approach? Nephrol Dial Transplant 2011; 26: 2069-2071
19. Spinowitz BS, Kausz AT, Baptista J et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605
20. Sonnweber T, Theurl I, Seifert M et al. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant 2011; 26: 977-987
21. Locatelli F, Andrulli S, Memoli B et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 991-998
22. Rossert J, Gassmann-Mayer C, Frei D et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007; 22: 794-800
23. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423
24. Pisoni RL, Fuller DS, Bieber BA et al. The DOPPS practice monitor for US dialysis care: trends through August 2011. Am J Kidney Dis 2012; 60: 160-165
25. Robinson BM, Larkina M, Li Y et al. Iron dosing and changes in serum TSAT, ferritin, and hemoglobin levels: implications of increasing IV iron dosing in the US. American Society of Neprology Annual Meeting, 2012 (Abstract)
26. Richardson D, Ford D, Gilg J et al. UK renal registry 11th annual report (December 2008): Chapter 9 Haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analyses. Nephron Clin Pract 2009; 111(Suppl 1): c149-c183
27. UK Renal Registry 14th Annual Report: Chapter 8 Haemoglobin, Ferritin and Erythropoietin amongst UK Adult Dialysis Patients in 2010: national and centre-specific analyses. Available at http ://www.renalreg.com/Report-Area/ Report%202011/Chap08-Renal11-web.pdf (13 January 2013, date last accessed)
28. Kovesdy CP, Estrada W, Ahmadzadeh S et al. Association of markers of iron stores with outcomes in patients with nondialysis- dependent chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 435-441
29. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080
30. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008; 3: 1691-1701
31. Coyne DW, Kapoian T, Suki W et al. DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984
32. Kapoian T, O'Mara NB, Singh AK et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19: 372-37933.
33. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632
34. Ali M, Rigolosi R, Fayemi AO et al. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1982; 1: 652-655
35. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741
36. Uehata T, Tomosugi N, Shoji T et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant 2012; 27: 1076-1083
37. Bárány P, Eriksson LC, Hultcrantz R et al. Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab 1997; 23: 273-276
38. Ruiz-Jaramillo Mde L, Guízar-Mendoza JM, Amador-Licona N et al. Iron overload as cardiovascular risk factor in children and adolescents with renal disease. Nephrol Dial Transplant 2011; 26: 3268-3273
39. Agarwal R. Iron, oxidative stress, and clinical outcomes. Pediatr Nephrol 2008; 23: 1195-1199
40. Brewster UC, Coca SG, Reilly RF et al. Effect of intravenous iron on haemodialysis catheter microbial colonization and bloodborne infection. Nephrology (Carlton) 2005; 10: 124-128
41. Canavese C, Bergamo D, Ciccone G et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004; 65: 1091-1098
42. Ghoti H, Rachmilewitz EA, Simon-Lopez R et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012; 89: 87-93
43. Rostoker G, Griuncelli M, Loridon C et al. Hemodialysis-associated hemosiderosis in the Era of erythropoiesis-stimulating Agents: A MRI Study. Am J Med 2012; 125: 991-999
44. Ferrari P, Kulkarni H, Dheda S et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 77-83
45. Streja E, Kovesdy CP, Greenland S et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727-736
46. Del Vecchio L, Locatelli F. Safety issues related to erythropoiesisstimulating agents used to treat anemia in patients with chronic kidney disease. Expert Opin Drug Saf 2012; 11: 923-31
47. Elliott S, Sinclair AM. The effect of erythropoietin on normal and neoplastic cells. Biologics 2012; 6: 163-189
48. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189
49. Skali H, Parving HH, Parfrey PS et al. TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 2011; 124: 2903-2908
50. Parfrey PS, Lauve M, Latremouille-Viau D et al. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 2009; 4: 755-762
51. Skali H, Lin J, Pfeffer MA et al. Hemoglobin stability in patients with anemia, CKD, and Type 2 diabetes: an analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm. Am J Kidney Dis 2013; 61: 238-46
52. Minutolo R, Zamboli P, Chiodini P et al. Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purif 2010; 30: 186-194
53. Akizawa T, Gejyo F, Nishi S et al. KRN321 STUDY Group. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Ther Apher Dial 2011; 15: 431-440
54. Tsubakihara Y, Gejyo F, Shinichi Nishi S et al. High target haemoglobin with erythropoiesis stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial 2012; 16: 529-40
55. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
56. Drüeke TB, Locatelli F, Clyne N et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
57. Singh AK, Szczech L, Tang KL et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
58. Locatelli F, Nissenson AR, Barrett BJ et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2008; 74: 1237-1240
59. Palmer SC, Navaneethan SD, Craig JC et al. Meta-analysis: erythropoiesis- stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33
60. Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the normal hematocrit trial. Kidney Int 2012; 82: 235-241
61. Besarab A, Bolton WK, Nissenson AR et al. The normal HCT trial re-revisited: what were the actual findings? Kidney Int 2012; 82: 242
62. Sack K. Unintended consequence for dialysis patients as drug rule changes. New York Times 11 May 2012
63. Murphy MF, Wallington TB, Kelsey P et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001; 113: 24-31
64. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and PulmonaryRehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50: e1-e157
65. Carson JL, Grossman BJ, Kleinman S et al. Clinical Transfusion Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012; 157: 49-58
66. Oliva EN, Dimitrov BD, Benedetto F et al. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 2005; 29: 1217-1219